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Introduction
Parkinson’s disease (PD) is a progressive neurode-
generative disease that affects 1–2% of people older
than 60 years of age (1). Although PD has long been
considered predominantly a motor disorder, its fre-
quent association with dementia has recently gained
increasing recognition (2–4). Patients with PD have
an almost sixfold increased risk of developing
dementia compared with age-matched individuals
without PD (5). In a 12-year population study of
patients with PD, the cumulative incidence of
dementia increased steadily with age and disease
duration reaching 80–90% by age 90 years (condi-
tional on survival) (6). Dementia contributes signiﬁ-
cantly to the morbidity and mortality of PD (7,8).
Key risk factors or correlates consistently associated
with PD dementia (PDD) are older age, more severe
parkinsonism (particularly rigidity, postural instabil-
ity and gait disturbance), male gender, certain psy-
chiatric symptoms (depression, psychosis) and mild
cognitive impairment (MCI) (9–11).
Mild cognitive impairment is a condition that can
occur as a transitional state between normal ageing
and dementia and has traditionally been used to
describe patients who frequently go on to develop
Alzheimer’s disease (AD) (12). An analogous concept
of PD-MCI has been proposed and recent cross-sec-
tional studies suggest that more than 20% of PD
patients meet criteria for PD-MCI with a majority
going on to develop PDD over time (13,14). Deﬁn-
ing PD-MCI offers an opportunity for further study
of cognitive impairment in PD and targets earlier
therapeutic intervention.
The cognitive proﬁle of PDD may be different
from that of AD. Speciﬁcally, impairments in atten-
tion, executive and visuo-spatial functions tend to
dominate in PDD, with memory encoding and lan-
guage abnormalities playing a less signiﬁcant role
than they do in AD (2,3). A recent analysis compar-
ing the proﬁles of cognitive impairment in 976
patients with AD or PDD suggested that diagnosis
could be predicted from the cognitive proﬁle with
74.7% accuracy (15). Worse performance by AD
patients on the orientation task and PDD patients on
the attentional task best distinguished the two diag-
nostic groups (15). Both groups showed memory
impairment, although AD patients performed worse
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SUMMARY
Parkinson’s disease (PD) has long been considered predominantly a motor disorder.
However, its frequent association with dementia, which contributes signiﬁcantly to
the morbidity and mortality of the condition, is gaining increasing recognition. PD
dementia (PDD) has a unique clinical proﬁle and neuropathology, distinct from Alz-
heimer’s disease (AD). Cholinergic deﬁcits, a feature of both AD and PDD, underlie
the rationale for cholinesterase inhibitor therapy in both conditions. In clinical prac-
tice, it is important that PDD should be recognised and appropriately treated. This
review aims to outline the recently proposed clinical diagnostic criteria for PDD
and to summarise the guidelines⁄recommendations published since 2006 on the
use of cholinesterase inhibitors in the management of PDD. Although the cholines-
terase inhibitor rivastigmine has recently been approved for the management of
PDD, there remains a need for the development of novel therapies that can affect
key mechanisms of the disease or prevent⁄delay patients with PD and mild cogni-
tive impairment from progressing to PDD.
Review Criteria
This review focuses primarily on the clinical
diagnostic criteria for PDD recently published by a
Task Force of the Movement Disorder Society
(MDS). In addition, guidelines ⁄ recommendations
published since 2006 on the use of cholinesterase
inhibitors for the management of PDD are
summarised. Articles were identiﬁed using MEDLINE
in January 2008 (search limits: last 5 years) using
the terms: dementia; treatment; guidelines; and
recommendations.
Message for the Clinic
A simple algorithm has been proposed to help
clinicians to recognise and accurately diagnose PDD
as a distinct dementia syndrome. Patients with this
condition can beneﬁt from treatment with
cholinesterase inhibitors.
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chiatric symptoms, common in both diseases, also
present themselves characteristically, with visual hal-
lucinations and rapid eye movement sleep behaviour
disorders occurring much more frequently in PDD
than in AD (16,17).
The classical motor features of PD include rigidity,
resting tremor, bradykinesia and postural instability.
These motor symptoms are believed to result from a
gradual loss of dopaminergic neurons projecting
from the substantia nigra to the striatum because of
the deposition of Lewy bodies constituted of a-syn-
uclein protein (18). However, the neuropathophysio-
logical underpinnings of dementia in PD are a
subject of continued debate (19). While AD pathol-
ogy may contribute to PDD in some cases (20),
recent research suggests that the neural substrate of
most cases of PDD is Lewy body⁄synuclein pathology
(21,22). Therefore, PDD appears to be distinct in
terms of its clinical proﬁle and neuropathology (19).
Nevertheless, both PDD and AD are associated with
marked cholinergic deﬁcits (to a greater extent in
PDD than in AD) (23,24) and it is these deﬁcits that
underlie the rationale for cholinesterase inhibitor ther-
apy in both conditions. The ﬁrst clinical evaluation of
a cholinesterase inhibitor in PDD comprised a small,
open-label study of tacrine (25). The suggestion of
clinical effectiveness in that study gave rise to a series
of open-label trials and case series to assess donepezil
(26–28), rivastigmine (29–31) and galantamine (32) in
PDD. Two small double-blind, placebo-controlled
trials appeared to demonstrate modest cognitive
beneﬁts for donepezil (33,34). However, only one large
(n = 541), double-blind, placebo-controlled cholines-
terase inhibitor trial has been published to date (11).
Statistically signiﬁcant effects of rivastigmine capsules
vs. placebo on a range of primary and secondary out-
come measures were observed including cognitive per-
formance, attention, executive function, activities of
daily living (ADLs) and behavioural symptoms (11).
In secondary analyses, these effects were particularly
marked in patients with clinical markers predictive of
a more aggressive course of disease, such as hallucina-
tions (35) and elevated plasma homocysteine levels at
baseline (36). Currently, donepezil, rivastigmine and
galantamine are widely approved for the treatment of
AD; rivastigmine is the only pharmacological agent
currently approved for the treatment of PDD in Eur-
ope, the USA and Canada. Last year in the USA,
a patch containing rivastigmine became the ﬁrst trans-
dermal treatment approved for both AD and PDD.
In contrast to AD, trial data of memantine are not
available for PDD.
In clinical practice, PDD often goes unrecognised
and, as a result, is not appropriately treated. The
expanding population of patients with PD (37), the
recognition that dementia is a very common non-
motor complication of PD and the recent FDA
approval of a cholinesterase inhibitor (rivastigmine)
to treat PDD have created a surge of interest in
recognising, diagnosing and treating PDD. As a
result, the Movement Disorder Society (MDS)
recruited a task force comprising 23 members repre-
senting various disciplines and geographical regions,
to propose clinical diagnostic criteria for PDD (10).
In addition, several guidelines⁄recommendations on
the use of different agents in the management of this
condition have been published since 2006 (38–41).
These guidelines and current evidence for the use of
cholinesterase inhibitors in PDD are reviewed here.
Clinical diagnostic criteria for PDD
Prior to the development of the MDS-proposed clin-
ical diagnostic criteria (10), PD patients were diag-
nosed with dementia according to the DSM-IV
criteria (42) on the basis of ‘dementia due to other
general medical conditions’. Unfortunately, within
these criteria, the section devoted to PDD is rather
generic and imprecise, with reference to cognitive
and motor slowing, executive dysfunction, impair-
ment in memory retrieval and frequent exacerbation
by depression. A comprehensive, systematic review of
the literature related to the epidemiological, cognitive
and neuropsychiatric motor and other clinical fea-
tures, ancillary examinations, and clinico-pathologi-
cal correlations enabled the MDS Task Force to
propose clinical criteria for the diagnosis of possible
and probable PDD (10).
The MDS Task Force proposed four clusters of
features requiring sequential consideration to deter-
mine whether a diagnosis of PDD is probable, possi-
ble or impossible (Figure 1). Following the
development of these criteria for PDD, the MDS
Task Force subsequently published a recommended
algorithm for diagnosing PDD (9). Thus, two ver-
sions of the MDS Task Force’s recommendations
exist: one tailored to the needs of clinicians requiring
a simple, practical, screening tool in the ofﬁce or at
the bedside, which is summarised in Table 1 (9) and
another, a more detailed approach for clinical moni-
toring, research studies or clinical trials (10). The
shorter algorithm for clinicians comprises ﬁve criteria
which, if all present, lead to a diagnosis of PDD.
Core features of probable PDD
The primary deﬁning feature of PDD is dementia
that develops in the setting of established PD (9,10).
Therefore, the critical ﬁrst step in the diagnosis
process is to identify idiopathic PD, prior to the
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two core features must be present: (i) a diagnosis of
PD according to the Queen Square Brain Bank crite-
ria (43) and (ii) PD developed prior to the onset of
dementia [PDD can be temporally distinguished
from dementia with Lewy bodies (DLB) by the
‘1-year rule’; in PDD, motor symptoms develop at
least 1 year before development of dementia, while
in DLB, the motor symptoms occur no more than
1 year prior to the onset of dementia and frequently
after the onset of dementia (44)].
In this case, a ‘dementia’ syndrome is deﬁned as
(i) impairment in at least two cognitive domains
and (ii) cognitive deﬁciency severe enough to impair
daily life (social, occupational or personal care) that
must be independent of impairment because of PD
motor symptoms. The MDS Task Force recom-
mended that the Mini-Mental State Examination
I. Core features
Diagnosis of PD +
Dementia syndrome
PDD diagnosis
II. Associated clinical features
Impairment of at least two
of four cognitive domains
(May be supported by behavioural symptoms)
III. Presence of features which
make diagnosis uncertain
IV. Presence of features which
make diagnosis impossible
Cognitive and behavioural symptoms 
presenting as a result of other 
conditions, for example:
￿  Co-existence of any abnormality
that could itself cause cognitive
impairment, but not cause dementia
￿  Unknown time interval between
onset of motor and cognitive symptoms 
￿  Acute confusion due to systemic diseases/
abnormalities or drug intoxication
￿  Major depression according to DSM IV
￿  Features of ‘probable vascular dementia’
according to NINDS-AIREN 
+
Probable
Possible
Impossible
Figure 1 Parkinson’s disease dementia (PDD) diagnosis overview based on the 2007 Movement Disorder Society
guidelines (9,10)
Table 1 A simple algorithm for clinician diagnosis of PDD, as recommended by the MDS Task Force
Criteria Assessment
1 A diagnosis of PD Queen’s Square Brain Bank Criteria
2 PD developed prior to the onset of dementia Patient⁄caregiver history or ancillary records
3 PD associated with a decreased global cognitive efﬁciency MMSE < 26
4 Cognitive deﬁciency severe enough to impair daily life Caregiver interview or pill questionnaire
5 Impairment of more than one cognitive domain Impairment of at least two of the following domains
Attention
Executive function
Visuo-constructive ability
Memory
Table adapted from Dubois, et al. (9) with the permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. Presence of one
of the following behavioural symptoms (apathy, personality changes, hallucinations, delusions or excessive daytime sleepiness) may
support the diagnosis of probable PDD. Some behavioural symptoms can be assessed with the four-item Neuropsychiatric Inventory
(hallucinations, depression, delusions and apathy). Refer to Figure 1 for concurrent features that may make PDD diagnosis uncer-
tain⁄impossible. PDD, Parkinson’s disease dementia; MDS, Movement Disorder Society; MMSE, Mini-Mental State Examination.
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for identifying cognitive impairment in PDD
patients – the MMSE is a simple and universally
applied scale that can be easily and quickly per-
formed in the clinical setting (9). An MMSE score
of 25 or below is proposed as the cut-off for identi-
fying clinically signiﬁcant cognitive impairment in
this population (9).
Associated clinical features of probable PDD
‘Associated clinical features’ are deﬁned along four
primary cognitive domains (attention, memory, exec-
utive and visuo-spatial functions) and a spectrum of
behavioural disorders (9,10). The MDS Task Force
recommended a number of tests from which the
clinician could choose to assess the four primary
cognitive domains (Table 2) and suggested that the
four-item Neuropsychiatric Inventory, which covers
hallucinations, depression, delusions and apathy,
might be useful in assessing behavioural symptoms
associated with PDD (9). A diagnosis of ‘probable’
PDD is made on the basis of a typical proﬁle of cog-
nitive deﬁcits (i.e. impairment in at least two of the
four cognitive domains supported by the presence of
at least one behavioural symptom). If dementia exists
in the presence of established PD, yet the associated
clinical features are not considered ‘typical’ (e.g. the
presence of a cognitive proﬁle more consistent with
AD), only ‘possible’ PDD should be diagnosed.
‘Possible’ PDD
There are numerous other features that do not neces-
sarily exclude PDD, but make the diagnosis of prob-
able PDD uncertain (i.e. ‘possible’ PDD instead)
(9,10). For example, if the time interval between the
onset of motor and cognitive symptoms is unknown,
it is difﬁcult to distinguish whether a patient has
DLB or PDD. History of medical or neurological
comorbidities other than PD can also be associated
with dementia (e.g. presence of signiﬁcant cerebro-
vascular disease identiﬁed by imaging techniques)
and their relevance must be considered when assign-
ing a diagnosis.
Certain other conditions or diseases that can cause
cognitive impairment and behavioural symptoms
(e.g. infection, dehydration, vitamin deﬁciency or
hormonal disturbances) make a reliable PDD diagno-
sis impossible and must be ruled out (9,10). Simi-
larly, delirium and cognitive impairment secondary
to PD treatments, the most common examples being
anticholinergics, dopamine replacement therapies
and benzodiazepines, must also be considered. A
diagnosis of dementia can generally be made only in
the absence of major depression, as the presence of
signiﬁcant depressive symptoms can impact on neu-
ropsychological performance. Yet, given that depres-
sion is frequently concurrent in patients with PD
(45), it should not be automatically considered a cri-
terion for exclusion.
Guidelines for management of PDD
As recognition of PDD as an independent dementia
syndrome increases, potential therapies are becoming
the focus of research efforts. Several guidelines⁄rec-
ommendations on the therapeutic management of
PDD have been published since 2006 (Table 3) (38–
41).
Table 2 Tests proposed by the MDS Task Force to assess cognitive deﬁcits in the clinical setting (9)
Cognitive domain Proposed tests Cut-off scores
Attention Serial 7s of the MMSE
Repeatedly subtract 7 starting at 100
Two or more incorrect responses
Months reversed
Give months of the year backwards
Omission of two or more months
Executive function Lexical ﬂuency
e.g. list words beginning with S in 1 min
Less than 9 words in a minute
Clock-drawing test
Draw clock with hands at ‘10 past 2’
Inability to draw clock or show time
Visuo-constructive ability MMSE pentagons
Copy two overlapping pentagons
Inability to draw pentagons
Memory 3-word recall of the MMSE
Free recall of three words
Missing at least one word
Impairment of at least two of the four domains is required to support a diagnosis of probable Parkinson’s disease dementia. MDS,
Movement Disorder Society; MMSE, Mini-Mental State Examination.
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A joint task force of the EFNS and the European sec-
tion of the MDS provided their recommendations for
the therapeutic management of PD in 2006, including
a section devoted to the management of non-motor
problems in PD, such as dementia (39). Although
they acknowledged that cognitive improvements in
patients with PDD treated with cholinesterase inhibi-
tors were modest, they classiﬁed clinical evidence
with rivastigmine and donepezil as class I and II stud-
ies respectively. For overall management, they recom-
mended both discontinuation of medications that
might impair cognition (e.g. anticholinergics and
amantadine) and the addition of cholinesterase inhib-
itor therapy either with rivastigmine (level A) or with
donepezil (level C) (39). Additionally, the authors
recommended that the addition of cholinesterase
inhibitor therapy with rivastigmine (level B) or
donepezil (level C) may also help in the treatment of
psychosis in this population (39).
Cochrane report
In a Cochrane meta-analysis on the use of cholines-
terase inhibitors in PDD (41), the large, randomised,
double-blind, placebo-controlled study of rivastig-
mine involving 541 patients was the sole study iden-
tiﬁed that met the inclusion criteria deﬁned in the
Cochrane Collaboration Handbook (46). The authors
concluded that this clinical study provided clear evi-
dence that rivastigmine has a beneﬁcial effect on cog-
nition and, to a lesser extent, ADLs in patients with
PDD. In general, rivastigmine was well tolerated and
no unexpected safety issues were reported. Adverse
events were predominantly cholinergic in nature, the
Table 3 Guidelines⁄recommendations published to date on the use of cholinesterase inhibitors for the symptomatic
treatment of PDD
Authors Task Force
Clinical evidence (class) Recommendation (level)
Rivastigmine Donepezil Rivastigmine Donepezil
Horstink et al. (39) EFNS and MDS-ES I II A C
Waldemar et al. (40) EFNS I – A –
Miyasaki et al. (38) AAN II I and II B B
Maidment et al. (41)* Cochrane Yes No Yes No
*One rivastigmine trial was the sole study identiﬁed that met the Cochrane inclusion criteria. The authors concluded that rivastigmine
improves cognition and activities of daily living. Clinical Evidence: Class I–IV, strongest to weakest clinical evidence. Recommendation:
Level A (established as effective, and should be used; based generally on at least two consistent class I studies) through to level U (data
inadequate or conﬂicting, not recommended; based on studies not meeting criteria for class I–III). MDS-ES, European section of the
MDS; PDD, Parkinson’s disease dementia; EFNS, European Federation of Neurological Societies; AAN, American Academy of Neurology.
Table 4 Cholinesterase inhibitor trials considered in the development of the AAN recommendations for the treatment
of PDD
References Indication
No. of
patients Study design
Study
duration
(weeks)
Observed beneﬁts
Cognition ADL Behaviour
Rivastigmine Emre et al. (11) PDD 541 Double-blind,
placebo-controlled
24 + + +
Donepezil Aarsland et al. (33) PDD 14 Double-blind,
placebo-controlled, crossover
10 + ND )
Ravina et al. (47) PDD 22 Double-blind,
placebo-controlled, crossover
10 )*N D )
+: Signiﬁcant beneﬁt observed in treated patients vs. placebo. ): No signiﬁcant beneﬁt observed in treated patients vs. placebo.
*Although a statistically signiﬁcant beneﬁt was observed on the study’s secondary cognitive measure (Mini-Mental State Examination),
there was no statistically signiﬁcant beneﬁt of donepezil treatment on the primary cognitive measure (ADAS-cog). PDD, Parkinson’s
disease dementia; AAN, American Academy of Neurology; ADL, activities of daily living; ADAS, Alzheimer’s Disease Assessment Scale;
ND, not determined.
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diarrhoea (which affected 29.0%, 16.6%, 10.2% and
7.2% of patients in the rivastigmine group versus
11.2%, 1.7%, 3.9% and 4.5% of those in the placebo
group respectively). Adverse events were the primary
reason for study discontinuation and resulted in the
withdrawal of 17.1% of patients from the rivastig-
mine-treated group and 7.8% of patients in the pla-
cebo group. Tremor was usually dose-titration
related, rarely severe (only one case of severe tremor
was reported) and did not result in signiﬁcant
increases in concomitant dopaminergic medication,
worsening of movement disorder assessments
[Uniﬁed Parkinson’s Disease Rating Scale (UPDRS)
part III score] or study discontinuations (11).
AAN practice parameter
In 2006, the dementia section of the American Acad-
emy of Neurology’s (AAN) evidence-based practice
parameters provided treatment recommendations for
patients with PDD (38). The AAN guidelines con-
cluded that the cholinesterase inhibitors, rivastigmine
and donepezil, are probably effective in improving
cognitive function and should be considered for the
treatment of dementia in PD (level B). However, the
AAN Subcommittee concluded that the magnitude of
their beneﬁt is modest [based on the number needed
to treat to obtain clinically meaningful (moderate or
marked) improvement on the Alzheimer’s Disease
Cooperative Study-Clinical Global Impressions of
Change (ADCS-CGIC) with rivastigmine] and tremor
may be exacerbated. These recommendations were
based on three clinical studies summarised in Table 4.
Conclusion
The introduction of guidelines for the diagnosis of
dementia associated with PD represents an important
milestone in its recognition as a distinct disease entity.
It is imperative that PDD is recognised and accurately
diagnosed by clinicians so that patients with this con-
dition can beneﬁt from appropriate treatment.
Currently, the cholinesterase inhibitor rivastigmine
is approved for this condition. However, there
remains a need to continue research into new and
better treatments, in particular those that affect key
disease mechanisms (e.g. a-synuclein aggregation) or
prevent or delay patients with MCI-PD from pro-
gressing to PDD.
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